SCHEMBL5367660

SCHEMBL5367660

Ic1[c]cc2oc3ccccc3c2c1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 5/20 0.47
KDM4E B2RXH2 3/20 0.47
ALDH1A1 P00352 3/20 0.47
HPGD P15428 3/20 0.47
MEN1 O00255 3/20 0.47
KMT2A Q03164 3/20 0.47
AHR P35869 3/20 0.47
SMN1; SMN2 Q16637 3/20 0.47
NPC1 O15118 2/20 0.47
RAB9A P51151 1/20 0.47
MAOA P21397 4/20 0.41
GLA P06280 1/20 0.41
CYP3A4 P08684 1/20 0.41
PGAM1 P18669 1/20 0.41
CASP1 P29466 1/20 0.41
CASP7 P55210 1/20 0.41
HSD17B10 Q99714 1/20 0.41
CYP1A2 P05177 2/20 0.39
CYP2D6 P10635 1/20 0.39
CYP2C19 P33261 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21295695 0.78 MAPT (0.47) MAPTKDM4EALDH1A1HPGDMEN1
SCHEMBL8964749 0.78 MAPT (0.47) MAPTKDM4EALDH1A1HPGDMEN1
SCHEMBL21295786 0.75 MAPT (0.44) MAPTKDM4EALDH1A1HPGDMEN1
SCHEMBL2089391 0.74 MEN1 (0.44) MAPTKDM4EALDH1A1HPGDMEN1
SCHEMBL16919496 0.73 AHR (0.71) MAPTKDM4EALDH1A1HPGDMEN1
SCHEMBL571563 0.73 AHR (0.71) MAPTKDM4EALDH1A1HPGDMEN1
SCHEMBL2549311 0.72 MAPT (0.59) MAPTKDM4EALDH1A1HPGDMEN1
Dibenzofuran SCHEMBL8207 0.72 MAPT (0.68) MAPTKDM4EALDH1A1HPGDMEN1
Dibenzofuran SCHEMBL9868133 0.72 MAPT (0.68) MAPTKDM4EALDH1A1HPGDMEN1
Dibenzofuran SCHEMBL29635704 0.72 MAPT (0.68) MAPTKDM4EALDH1A1HPGDMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7202265-B2 Indolinone combinatorial libraries and related products and methods for the treatment of disease SUGEN, INC. (US) 2007-04-10 US disclosed
US-20050197382-A1 Indolinone combinatorial libraries and related products and methods for the treatment of disease SUGEN, INC. 2005-09-08 US disclosed
EP-1320533-A4 PRODRUGS OF A 7-ACYLAMINO-3-HETEROARYLTHIO-3-CEPHEM CARBOXYLIC ACID ANTIBIOTIC ESSENTIAL THERAPEUTICS INC (US) 2004-12-15 EP disclosed
US-6723716-B1 BACTERICIDE FOR STAPHYLOCOCCUS ESSENTIAL THERAPEUTICS, INC. 2004-04-20 US disclosed
EP-1320533-A1 PRODRUGS OF A 7-ACYLAMINO-3-HETEROARYLTHIO-3-CEPHEM CARBOXYLIC ACID ANTIBIOTIC Essential Therapeutics, Inc. (US) 2003-06-25 EP disclosed
US-20030108946-A1 Indolinone combinatorial libraries and related products and methods for the treatment of disease SUGEN, INC. 2003-06-12 US disclosed
EP-1247803-A2 Indolinone compounds suitable for modulation of protein kinases Sugen, Inc. (US) 2002-10-09 EP disclosed
EP-1222194-A1 7-ACYLAMINO-3-HETEROARYLTHIO-3-CEPHEM CARBOXYLIC ACID ANTIBIOTICS AND PRODRUGS THEREOF Essential Therapeutics, Inc. (US) 2002-07-17 EP disclosed
WO-2002024708-A1 PRODRUGS OF A 7-ACYLAMINO-3-HETEROARYLTHIO-3-CEPHEM CARBOXYLIC ACID ANTIBIOTIC ESSENTIAL THERAPEUTICS, INC. (US) 2002-03-28 WO disclosed
US-20020022626-A1 Indolinone combinatorial libraries and related products and methods for the treatment of disease TANG PENG CHO (US) 2002-02-21 US disclosed
US-5698547-A 7-(ACYLAMINO)-3-(ARYLTHIO)-3-CEPHEM-4-CARBOXYLIC ACIDS WHICH EXHIBIT ANTIBACTERIAL ACTIVITY AGAINST ORGANISMS RESISTANT TO BETA-LACTAM ANTIBIOTICS MICROCIDE PHARMACEUTICALS, INC. (US) 1997-12-16 US disclosed
US-5688786-A MODIFIED CEPHALOSPORIN MICROCIDE PHARMACEUTICALS, INC. (US) 1997-11-18 US disclosed
WO-1997013772-A2 CEPHALOSPORIN ANTIBIOTICS MICROCIDE PHARMACEUTICALS, INC. (US) 1997-04-17 WO disclosed
US-5607926-A ACTIVE AGAINST METHICILLIN RESISTANT BACTERIA MICROCIDE PHARMACEUTICALS, INC. (US) 1997-03-04 US disclosed
US-5604218-A EXHIBITS ACTIVITY AGAINST METHICILLIN RESISTANT BACTERIA MICROCIDE PHARMACEUTICALS, INC. (US) 1997-02-18 US disclosed
EP-0754184-A1 CEPHALOSPORIN ANTIBIOTICS Microcide Pharmaceuticals, Inc. (US) 1997-01-22 EP disclosed
US-5593986-A Cephalosporin antibiotics MICROCIDE PHARMACEUTICALS, INC. (US) 1997-01-14 US disclosed
WO-1996038448-A1 β-LACTAM ANTIBIOTICS MICROCIDE PHARMACEUTICALS, INC. (US) 1996-12-05 WO disclosed
WO-1996038450-A1 CEPHALOSPORIN ANTIBIOTICS MICROCIDE PHARMACEUTICALS, INC. (US) 1996-12-05 WO disclosed
WO-1995026966-A1 CEPHALOSPORIN ANTIBIOTICS MICROCIDE PHARMACEUTICALS, INC. (US) 1995-10-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020022626-A1 Indolinone combinatorial libraries and related products and methods for the treatment of disease FRK, PTK2, DSTYK MAPT 3115/4885KDM4E 2438/4885ALDH1A1 2206/4885
US-20050197382-A1 Indolinone combinatorial libraries and related products and methods for the treatment of disease FRK, PTK2, DSTYK MAPT 3048/4885KDM4E 2527/4885ALDH1A1 2044/4885
US-20030108946-A1 Indolinone combinatorial libraries and related products and methods for the treatment of disease FRK, PTK2, DSTYK MAPT 3115/4885KDM4E 2438/4885ALDH1A1 2206/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.